Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment, respectively. Patient demographic and clinical characteristics, as well as treatment received prior and subsequent to olaparib + abiraterone, will also be described. The study plans to enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib until 1 year post last patient in.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem raka gruczołu krokowego (adenokarcinoma)
- •Zaawansowany rak prostaty oporny na leczenie hormonalne
- •Rozpoczęcie leczenia kombinacją olaparibu i abirateronu
- •Gotowość do podpisania zgody na uczestnictwo w badaniu
✗ Disqualifies
- •Uczestnictwo w innym badaniu klinicznym nad lekami na raka prostaty w ciągu ostatnich 30 dni przed rozpoczęciem olaparibu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- Male only
Locations (34)
Research Site
Aschaffenburg, Germany
Research Site
Augsburg, Germany
Research Site
Bergisch Gladbach, Germany
Research Site
Berlin, Germany
Research Site
Bonn, Germany
Research Site
Cologne, Germany
Research Site
Dresden, Germany
Research Site
Duisburg, Germany
Research Site
Eisenach, Germany
Research Site
Eisleben Lutherstadt, Germany
Research Site
Frankfurt, Germany
Research Site
Greifswald, Germany
Research Site
Halle, Germany
Research Site
Hamburg, Germany
Research Site
Hanover, Germany
Research Site
Heidelberg, Germany
Research Site
Heinsberg, Germany
Research Site
Herzogenaurach, Germany
Research Site
Leipzig, Germany
Research Site
Lübeck, Germany
Research Site
Lüneburg, Germany
Research Site
Magdeburg, Germany
Research Site
Marburg, Germany
Research Site
Mülheim, Germany
Research Site
Münster, Germany
Research Site
Neunkirchen, Germany
Research Site
Nuremberg, Germany
Research Site
Rüsselsheim am Main, Germany
Research Site
Saalfeld, Germany
Research Site
Speyer, Germany
Research Site
Trier, Germany
Research Site
Tübingen, Germany
Research Site
Westerstede, Germany
Research Site
Wetzlar, Germany
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.